FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Receptor patents



      
           
This page is updated frequently with new Receptor-related patent applications. Subscribe to the Receptor RSS feed to automatically get the update: related Receptor RSS feeds. RSS updates for this page: Receptor RSS RSS


Date/App# patent app List of recent Receptor-related patents
10/23/14
20140316140
 Dosing regimen for a selective s1p1 agonist patent thumbnailDosing regimen for a selective s1p1 agonist
The present invention relates to a dosing regimen for a selective s1p1 receptor agonist, whereby the selective s1p1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective s1p1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective s1p1 receptor agonist.. .
10/23/14
20140316139
 Tricyclic compounds, compositions, and methods patent thumbnailTricyclic compounds, compositions, and methods
Or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity..
10/23/14
20140316132
 Modulators of toll-like receptors patent thumbnailModulators of toll-like receptors
Pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.. .
10/23/14
20140316116
 Methods for screening for binding partners of g-protein coupled receptors patent thumbnailMethods for screening for binding partners of g-protein coupled receptors
A method of producing a conformational specific binding partner of a gpcr, the method comprising: a) providing a mutant gpcr of a parent gpcr, wherein the mutant gpcr has increased stability in a particular conformation relative to the parent gpcr; b) providing a test compound; c) determining whether the test compound binds to the mutant gpcr when residing in a particular conformation; and d) isolating a test compound that binds to the mutant gpcr when residing in the particular formation. Methods of producing gpcrs with increased stability relative to a parent gpcr are also disclosed..
10/23/14
20140315987
 Cholecystokinin b receptor (cckbr) mini-promoters patent thumbnailCholecystokinin b receptor (cckbr) mini-promoters
Isolated polynucleotides comprising a cckbr mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
10/23/14
20140315965
 Bis-(aryl/heteroaryl)-methylene compounds, pharmaceutical compositions containing same and their use for treating cancer patent thumbnailBis-(aryl/heteroaryl)-methylene compounds, pharmaceutical compositions containing same and their use for treating cancer
The present disclosure relates to novel compounds having vitamin d receptor agonist and histone deacetylase inhibitory efficacy as well as methods for reducing or inhibiting the proliferation of cancer cells or for treating cancer.. .
10/23/14
20140315964
 Dosing regimen for a selective s1p1 receptor agonist patent thumbnailDosing regimen for a selective s1p1 receptor agonist
The present invention relates to a dosing regimen for a selective s1p1 receptor agonist, whereby the selective s1p1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective s1p1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective s1p1 receptor agonist.. .
10/23/14
20140315963
 Heterocyclic acetamide compound patent thumbnailHeterocyclic acetamide compound
[means for solution] the present inventors have studied a compound which has a dopamine d1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, parkinson's disease, alzheimer's disease, huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine d1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine d1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, parkinson's disease, alzheimer's disease, huntington's disease, drug addictions, or the like..
10/23/14
20140315957
 Androgen receptor antagonists and uses thereof patent thumbnailAndrogen receptor antagonists and uses thereof
The present invention relates to novel substituted thioimidazolidinone compounds and pharmaceutical compositions comprising such compounds for treatment of androgen receptor-associated diseases or disorders, such as prostate cancer, benign prostatic hypertrophy, male hair loss, muscle loss, acne and hirsutism.. .
10/23/14
20140315940
 Morphinan compounds patent thumbnailMorphinan compounds
This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has nmda antagonist activity..
10/23/14
20140315923
Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
Wherein r1, r2, q1, q2, q3, q4, x, m, n, p and s are as described herein. More specifically, the compounds of this invention are modulators of h3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by h3 receptors including diseases associated with the central nervous system.
10/23/14
20140315922
Method of treating parkinson's disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity
Compositions and methods for treatment of parkinson's disease to reduce the negative side effects of the disease by administering a therapeutically effective diarylmethylpiperazine compound which exhibits delta opioid receptor agonist activity, and optionally, mu receptor antagonist activity.. .
10/23/14
20140315919
Highly selective sigma receptor ligands
In which r1 can be a radical of an optionally substituted c-4 to c-7 n-containing heterocycle such as, for example, radicals of optionally substituted piperidines, optionally substituted piperazines, optionally substituted tetrahydropyridines, optionally substituted azepanes, tertiary amines (cyclic or acyclic), isoindoline-1,3-dione, or optionally substituted tetrahydroisoquinolones (aromatically substituted): r2,3,4,5,6 can each independently be any one or combinations of the following moieties, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanate, isocyanate optionally substituted anilino, halogens, ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic, acetylene, deuterium, or tritium; y can be either ch, ch2, o, s, och2, n—r, n—ar, c—r, c—ar; z can be either h, o, s, s—r or nr. R groups can be either h, aryls, alkyls, or cycloalkyls; “n” can be 1 to 5 carbons in length and stereoisomers, functional analogs, and pharmaceutically acceptable salts thereof and wherein the moiety bridging r1 and n can be optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene and where the alkylene group can include an inserted c3-c5 cycloalkyl group, aromatic and heterocyclic group..
10/23/14
20140315912
Novel pyrrolidine derived beta 3 adrenergic receptor agonists
The present invention provides compounds of formula (i), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor. (i)..
10/23/14
20140315903
1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
Wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mglur2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mglur2 subtype of metabotropic receptors is involved.
10/23/14
20140315900
Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a dihydropyrazino-pyrazine compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.. .
10/23/14
20140315888
Novel heterocyclic derivatives and their uses
The present invention relates to novel heterocyclic compounds useful in preparing drugs for treatment of diseases associated with various functions of the histamine 4 receptor. Especially, the said drugs are useful for treatment of inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itch, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritic pain, autoimmune thyroid disease, immune-mediated (also known as type i) diabetes, lupus, post-operative adhesions, vestibular disorders and cancer..
10/23/14
20140315881
Compounds and methods
The present invention relates to novel retinoid-related orphan receptor gamma (rorγ) modulators and their use in the treatment of diseases mediated by rorγ.. .
10/23/14
20140315880
3,6-diazabicyclo[3.1.1]heptaines as neuronal nicotinic acetycholine receptor ligands
The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (cns).. .
10/23/14
20140315877
Nicotinic receptor non-competitive antagonists
The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.. .
10/23/14
20140315866
Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound..
10/23/14
20140315825
Anti-cancer compositions containing wnt decoy receptor
The present invention relates to a composition for preventing or treating cancer comprising wnt decoy receptor. The composition of the present invention or the expression product thereof inhibits cancer generation, growth, proliferation and metastasis, and induces apoptosis of cancer cells, by binding to wnt ligand and blocking ligand-receptor interactions, therefore may be effectively used as an anti-cancer agent..
10/23/14
20140315809
Calcimimetics and methods for their use
Methods for treating subjects suffering from chronic kidney disease-mineral and bone disorder or other disorders resulting in primary or secondary hyperparathyroidism are described. The methods are effective in reducing serum parathyroid hormone (pth) levels and calcium levels in patients who undergo hemodialysis.
10/23/14
20140315801
Methods of treatment of cell proliferative and/or ophthalmic diseases, disorders and conditions using inhibitors of protein tyrosine kinase activity
This invention relates to methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions using compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to the methods of treatment which utilize compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of vegf receptor signaling..
10/23/14
20140315800
Glycosylated polypeptide and drug composition containing said polypeptide
[problem] to provide a glycosylated polypeptide having affinity to somatostatin receptors and, compared to somatostatins, having improved in-blood stability. [solution] the glycosylated polypeptide is characterized by at least two amino acids in a somatostatin or an analogue thereof being replaced by glycosylated amino acids..
10/23/14
20140315796
Modulators of protease activated receptors
The present invention provides novel compounds of the formula (i), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type ii diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities.. .
10/23/14
20140315795
Compositions and methods for selective delivery of oligonucleotide molecules to cell types
The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalised by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes..
10/23/14
20140315758
Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
Disclosed are: a nucleotide sequence and an amino acid sequence for cdr3 region of t-cell receptor (tcr) gene of wt1-specific cytotoxic t-cell (ctl) for wt1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence.. .
10/23/14
20140315752
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of stanniocalcin-1, antithrombin-iii, toll-like receptor 2, triiodothyronine (t3), thyroxine (t4), extracellular matrix protein 1, coagulation factor xiii a chain, coagulation factor xiii b chain, interleukin-17f, interleukin-22, vitronectin, progesterone, estradiol, growth/differentiation factor 15, and proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic biomarkers in renal injuries..
10/23/14
20140315735
Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
Disclosed are: a nucleotide sequence and an amino acid sequence for cdr3 region of t-cell receptor (tcr) gene of wt1-specific cytotoxic t-cell (ctl) for wt1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence.. .
10/23/14
20140315725
Sequence analysis of complex amplicons
The invention is directed to methods of generating sequence profiles of populations of nucleic acids, whose member nucleic acids contain regions of high variability, such as populations of nucleic acids encoding t cell receptors or b cell receptors. In one aspect, the invention provides pluralities of sets of primers for generating nested sets of templates from nucleic acids in such populations, thereby insuring the production of at least one template from which sequence reads are generated, despite such variability, or despite limited lengths or quality of sequence reads.
10/23/14
20140315304
Reprogramming t cells and hematopoietic cells
Methods and compositions relating to the production of induced pluripotent stem cells (ips cells) are disclosed. For example, induced pluripotent stem cells may be generated from cd34+ hematopoietic cells, such as human cd34+ blood progenitor cells, or t cells.
10/23/14
20140315299
Stable proteins
The invention provides a fusion protein comprising, from n-terminus to c-terminus: a) a first portion of a family b g-protein coupled receptor (gpcr) that comprises transmembrane helix (tm)-1, tm2 and tm3 of the gpcr; b) a stable protein domain; and c) a second portion of the gpcr comprising tm4, tm5, tm6 and tm7 of the gpcr. The invention also provides a method of crystallising a gpcr comprising providing the fusion protein of the invention and crystallising it to obtain crystals..
10/23/14
20140315220
Cellular recognition conjugates and methods of use for the histological analysis of cancer tissue using maldi-ms imaging
Disclosed are conjugates that can bind to one or more site on cancer cell surface, for example, surface proteins, compound specific receptors and carbohydrates that comprise the surface of specific cell types. The disclosed conjugates can thereby serve as indicators identifying the presence of cancerous tissue..
10/23/14
20140315210
Methods relating to idiopathic pulmonary fibrosis (ipf)
The invention concerns methods of classifying patients having idiopathic pulmonary fibrosis (ipf) and of determining a preferred therapy for the treatment of ipf based on the presence or absence of the c1234t polymorphism in the toll-like receptor 3 (tlr3) gene of such patients.. .
10/23/14
20140314839
Controlled-release peptide compositions and uses thereof
Controlled-release formulations of carboxy-terminal c5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a c5a receptor, are provided.. .
10/23/14
20140314838
Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs for treating contrast-induced nephropathy
Featured are methods and compositions for treating, managing, preventing, or reducing injury to the kidney of a mammal (e.g., a human) caused by one or more iodinated radiocontrast media. The methods include administering an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (pacap)-like compounds, which includes native human pacap38, native human pacap27, native human vasoactive intestinal peptide (vip), their agonists, analogs, fragments, and derivatives, with activities toward one or more of the pacap/vip receptors, including all of their various isoforms.
10/23/14
20140314799
Methods, agents and peptides for inhibiting matrix metalloproteinase-2 signaling
Screening assays and methods of using same for screening to identify modulator agents or compounds that affect matrix metalloproteinase-2 (mmp-2) mediated activation of toll-like receptor-2 (tlr-2) are described herein. Pharmaceutical and immunogenic compositions comprising agents or compounds that modulate mmp-2 mediated activation of tlr-2 are also encompassed.
10/23/14
20140314769
Neutralizing antibodies and methods of use thereof
This invention provides monoclonal antibodies that recognize the toll-like receptor 4/md-2 receptor complex, and monoclonal antibodies that recognize the tlr4/md2 complex as well as tlr4 when not complexed with md-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics.
10/23/14
20140314764
Bi-specific antibodies for medical use
A bispecific antibody format devoid of an active fc moiety comprising a monovalent binding site for a death receptor and at least one binding site for a cell surface antigen expressed on b-cells, for use in the treatment or prevention of b cell mediated autoimmune diseases.. .
10/23/14
20140314711
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
The invention relates to il-22 polypeptides, il-22 fc fusion proteins and il-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to il-22 receptor associated reagents and methods of use thereof..
10/23/14
20140314704
Treatment of b cell lymphomas
Controlled-release formulations of carboxy-terminal c5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a c5a receptor, are provided.. .
10/23/14
20140312879
Method to realize electronic field-effect transistor sensors
A transistor includes at least one conductive layer, at least one gate dielectric layer and at least one semiconducting film deposited on top of a receptor molecule layer previously deposited or covalently linked to the surface of the gate dielectric. The layer of biological material includes single or double layers of phospholipids, layers made of proteins such as receptors, antibodies, ionic channels and enzymes, single or double layers of phospholipids with inclusion or anchoring of proteins such as: receptors, antibodies, ionic channels and enzymes, layers made of oligonucleotide (dna, rna, pna) probes, layers made of cells or viruses, layers made of synthetic receptors for example molecules or macromolecules similar to biological receptors for properties, reactivity or steric aspects..
10/23/14
20140311014
Pest control system, pest control method and pest control program
Provided are a pest control system, a pest control method and a pest control program which can destroy pests from agriculture with no harmful effects to other useful organisms, crops and humans as no pesticides are used. The pest control system comprises; a detection beam emitter for emitting a detection beam for detecting the pests; a reflected signal receptor for receiving a reflected signal reflected from an object irradiated with the detection beam; a pest detecting means for detecting the pests by comparing a reflected data obtained from the reflected signal with a signature data having a signature of target pests stored in a signature data storage means; a targeting means for aiming a destruction beam at said pests for destroying the pests upon detecting the pests; and a destruction beam emitter for emitting the destruction beam to the pests up on detecting the pests..
10/16/14
20140310828
Targeted modification of rat genome
Compositions and methods are provided for modifying a rat genomic locus of interest using a large targeting vector (ltvec) comprising various endogenous or exogenous nucleic acid sequences as described herein. Compositions and methods for generating a genetically modified rat comprising one or more targeted genetic modifications in their germline are also provided.
10/16/14
20140309713
Long-term electrostimulation of receptors
An electrostimulation device includes an implantable internal unit, which includes an array of electrodes assembled on or in a housing, and affixing structure for affixing the unit with respect to a targeted anatomy of a patient, a microprocessor mounted in the housing and in communication with the electrodes, a transceiver mounted in the housing and in communication with the microprocessor, and a power supply for providing power to the electrodes, the microprocessor and the transceiver.. .
10/16/14
20140309681
Bariatric device and method
A bariatric device and method of causing at least partial satiety in a recipient includes positioning a body in a recipient, the body having a wall defining a lumen, the wall configured to generally conform to the shape and size of the proximal cardiac portion of the stomach. Force is exerted with the wall on the proximal cardiac portion of the stomach in the absence of food thereby activating receptors located in the proximal cardiac portion of the stomach, thereby influencing a neurohormonal feedback mechanism of the recipient to cause at least partial satiety by augmenting fullness caused by food and simulating fullness in the absence of food..
10/16/14
20140309487
Targeted modification of rat genome
Compositions and methods are provided for modifying a rat genomic locus of interest using a large targeting vector (ltvec) comprising various endogenous or exogenous nucleic acid sequences as described herein. Compositions and methods for generating a genetically modified rat comprising one or more targeted genetic modifications in their germline are also provided.
10/16/14
20140309300
Bicyclic labdane diterpenes for use in the treatment of trpc6 associated diseases
The present invention relates to bicyclic labdane diterpenes for use in the treatment of a disease associated with activation of transient receptor potential cation channel 6 (trpc6), preferably a pulmonary or a renal disease. In one aspect the invention relates to the use of a bicyclic labdane diterpene for blocking calcium transport via trpc6.
10/16/14
20140309264
Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
Wherein a, y, z, r3 to r6, r20 to r22 and r50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (edg-2, edg2), which is activated by lysophosphatidic acid (lpa) and is also termed as lpa1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example.
10/16/14
20140309262
Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.. .
10/16/14
20140309261
Novel 2-substituted benzimidazoles as selective androgen receptor modulators (sarms)
The present invention is directed to a novel 2-substituted benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.. .
10/16/14
20140309252
Compositions and methods for reducing food cravings
Disclosed are compositions for reducing food cravings, comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is an α-msh agonist. Also disclosed are methods of reducing food cravings, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-msh activity..
10/16/14
20140309251
Spirothienopyran-piperidine derivatives as orl-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse
For the treatment of alcohol use disorders is described.. .
10/16/14
20140309227
Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use
The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (i) wherein ring a, rq, -l-, r1, n, r2, and r3 are as defined herein. The compounds of the invention are useful as non-competitive mglur2 antagonists, or mglur2 negative allosteric modulators (nams), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mglur2-nam receptor is involved, such as alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
10/16/14
20140309192
Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
That are useful in methods of treatment and alleviation of diseases and disorders of the heart, brain, kidney, immune, and reproductive system resulting from ischemia, or reperfusion subsequent to ischemia, and any downstream complication(s) related thereto. The present invention further relates to methods of treatment and alleviation of diseases and disorders of the vasculature resulting from vasoconstriction or hypertension and any downstream complication(s) resulting from elevated blood pressure and/or reduced tissue perfusion..
10/16/14
20140309190
Bicyclic aryl sphingosine 1-phosphate analogs
Compounds that have agonist activity at one or more of the s1p receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at s1p receptors..
10/16/14
20140309185
Inhibiting g protein coupled receptor 6 kinase polypeptides
This document relates to inhibitors of g protein coupled receptor 6 kinase (grk6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.. .
10/16/14
20140309127
Methods of detecting bladder cancer
Compositions and methods for detecting bladder cancer are provided. In some embodiments, methods of detecting low grade bladder cancer are provided.
10/16/14
20140308754
Flow-valve diagnostic microfluidic system
A system for detecting concentration of a target in a solution where sample fluid is passed into a microchannel with wall coated with the receptor that reacts and crosslinks with the target to constrict the channel and slow or stop sample flow through the microchannel. Concentration of the target is determined by measuring length of the sample filled channel..
10/16/14
20140308751
Assays for analyte homologs
Methods include adjusting a contribution of one of two analyte homologs to an amount of signal obtained in an assay for determining a total amount of the two analyte homologs in a sample. A non-assay receptor is employed that has a greater binding affinity for whichever of the two analyte homologs whose contribution to the amount of signal is to be adjusted.
10/16/14
20140308348
Flurbiprofen and muscle relaxant combinations
This invention is a novel pharmaceutical composition comprising flurbiprofen or a pharmaceutically acceptable salt thereof in combination with an α-2 adrenergic receptor agonist or a gamma-aminobutiric acid receptor agonist with anti-inflammatory, analgesic and myorelaxant activity.. .
10/16/14
20140308342
Reprogramming urokinase into an antibody-recruiting anticancer agent
The present invention relates to chimeric (preferably, bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds preferably covalently bind to the urokinase receptor and recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and/or antibody-dependent cellular cytotoxicity (adcc) against a large number and variety of cancers, thus providing cancer cell death and/or an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer..
10/16/14
20140308299
Combination immunotherapy for the treatment of cancer
Agonists to icos in combination with a blocking agent to a t cell inhibitory receptor (e.g., ctla-4, pd-1, etc.) are demonstrated herein to be useful for the treatment of tumors.. .
10/16/14
20140308298
Diagnostic and treatment of an androgen-independent prostate cancer
The present invention relates to a method for monitoring the tumor growth of an androgen-independent prostate cancer in a subject, by determining the amount of at least one adrenomedullin receptor and optionally adrenomedullin in a prostate cancer cell obtained from said subject. The present invention also relates to a pharmaceutical composition comprising an anti-adrenomedullin antagonist antibody and/or at least one anti-adrenomedullin receptor antagonist antibody for treating an androgen-independent prostate cancer..
10/16/14
20140308294
Anti-il-1r1 inhibitors for use in cancer
The invention relates to polypeptides that block or inhibit the interleukin-1 receptor 1 (il-1r1), the interaction of il-1beta with il-1r1 or the interaction between il-1r1 and interleukin-1 receptor accessory protein (il-1racp). The invention relates specifically to therapeutic polypeptides that target specifically il-1r1 present on tumor cells, cancer stem cells, and cancer stem cells which are resistant to chemotherapy or radiotherapy.
10/16/14
20140308288
Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
An antibody of the invention interacts with human dr5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-dr5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated.
10/16/14
20140308281
Antibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates
The invention concerns antibodies directed against cd127, i.e. The alpha chain of the receptor for interleukin7 (il-7), especially the receptor for human il-7 expressed on human cells (designated human il-7r alpha or il-7ra) or the tslp receptor.
10/16/14
20140308276
Anti-ox40 antibodies and methods of using the same
Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human ox40 are disclosed. Preferred antibodies have high affinity for ox40 receptor and activate the receptor in vitro and in vivo.
10/16/14
20140308259
Isolated b7-h4 specific compositions and methods of use thereof
The present invention relates to b7-h4-specific chimeric antigen receptor compositions and methods of use thereof.. .
10/16/14
20140308206
Fc receptor binding proteins
The disclosure relates to antibodies that bind fcrn and methods of using these antibodies.. .
10/16/14
20140308204
Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
The present invention provides methods of monitoring and measuring tumor-associated free psa (“fpsa”) with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.7557

3363

4 - 0 - 76